ExThera Medical Corporation
ExThera Medical develops and commercializes extracorporeal blood filtration devices, including the Seraph 100 Microbind Affinity Blood Filter and ONCObind, for removing harmful substances from the bloodstream. The company aims to serve healthcare professionals and patients worldwide, with a focus on treating severe infections, sepsis, COVID-19, and metastatic cancer. Their products have demonstrated life-saving capabilities and are involved in clinical trials and regulatory processes to expand their indications.
Industries
Nr. of Employees
small (1-50)
ExThera Medical Corporation
757 Arnold Drive, Suite B, Martinez, California 94553
Patents
Methods for removing cytokines from blood with surface immobilized polysaccharides
US-11123466-B2
View DetailsMethods for removing cytokines from blood with surface immobilized polysaccharides
US-10086126-B2
View DetailsMethods for removing cytokines from blood with surface immobilized polysaccharides
US-9408962-B2
View DetailsMethod for removing cytokines from blood with surface immobilized polysaccharides
US-8758286-B2
View Details
Methods for removing cytokines from blood with surface immobilized polysaccharides
US-11123466-B2
View DetailsMethods for removing cytokines from blood with surface immobilized polysaccharides
US-10086126-B2
View DetailsMethods for removing cytokines from blood with surface immobilized polysaccharides
US-9408962-B2
View DetailsMethod for removing cytokines from blood with surface immobilized polysaccharides
US-8758286-B2
View DetailsProducts
Affinity-based hemoperfusion blood filter
Disposable extracorporeal blood filter employing affinity adsorption media to bind and remove pathogens, circulating tumor cells and sepsis mediators from whole blood during extracorporeal circulation.
Oncology-focused hemoperfusion procedure (investigational)
Investigational extracorporeal hemoperfusion procedure using affinity adsorption media to capture and reduce circulating tumor cells as an adjunct to cancer therapy; studied under feasibility and investigational device protocols.
Affinity-based hemoperfusion blood filter
Disposable extracorporeal blood filter employing affinity adsorption media to bind and remove pathogens, circulating tumor cells and sepsis mediators from whole blood during extracorporeal circulation.
Oncology-focused hemoperfusion procedure (investigational)
Investigational extracorporeal hemoperfusion procedure using affinity adsorption media to capture and reduce circulating tumor cells as an adjunct to cancer therapy; studied under feasibility and investigational device protocols.
Services
Design, sponsorship and operational support for randomized controlled trials, observational registries and feasibility studies evaluating extracorporeal blood purification therapies.
Establishment of regional distribution and co-marketing agreements to enable device supply and clinical adoption in target markets.
Design, sponsorship and operational support for randomized controlled trials, observational registries and feasibility studies evaluating extracorporeal blood purification therapies.
Establishment of regional distribution and co-marketing agreements to enable device supply and clinical adoption in target markets.
Expertise Areas
- Extracorporeal blood purification
- Sepsis and bloodstream infection management
- Adjunctive oncology approaches targeting circulating tumor cells
- Clinical trial design and multicenter trial operations
Key Technologies
- Hemoperfusion / extracorporeal blood purification
- Affinity adsorption microbeads with immobilized heparin
- Hemoadsorption media for pathogen and circulating tumor cell capture
- Integration with extracorporeal circuits (dialysis, ECMO)
News & Updates
A study published in Nature's Scientific Reports found that the Seraph 100 blood filter significantly reduced pathogen load in septic patients following cardiac surgery, leading to faster recovery and lower incidence of kidney injury.
Research demonstrated the potential of Seraph 100 to remove circulating tumor cells, which may help in reducing metastasis and improving survival in pancreatic cancer.
The company was awarded for its innovative approach to treating sepsis with blood filtration technology.
The trial demonstrated the safety and initial signals of efficacy of the ONCObind device in removing circulating tumor cells in pancreatic cancer patients.
The company is conducting a clinical trial to evaluate the efficacy of the ONCObind device in removing circulating tumor cells from blood, potentially reducing metastasis and improving survival.
The Seraph 100 device has been authorized by the FDA under EUA for the treatment of COVID-19, marking a significant regulatory milestone.
A study published in Nature's Scientific Reports found that the Seraph 100 blood filter significantly reduced pathogen load in septic patients following cardiac surgery, leading to faster recovery and lower incidence of kidney injury.
Research demonstrated the potential of Seraph 100 to remove circulating tumor cells, which may help in reducing metastasis and improving survival in pancreatic cancer.
The company was awarded for its innovative approach to treating sepsis with blood filtration technology.
The trial demonstrated the safety and initial signals of efficacy of the ONCObind device in removing circulating tumor cells in pancreatic cancer patients.
The company is conducting a clinical trial to evaluate the efficacy of the ONCObind device in removing circulating tumor cells from blood, potentially reducing metastasis and improving survival.
The Seraph 100 device has been authorized by the FDA under EUA for the treatment of COVID-19, marking a significant regulatory milestone.